Table 2 Patient characteristics upon stratification into two groups by the rate of reduction in thyroid volume
High reduction rate group | Low reduction rate group | P -value | |
---|---|---|---|
Gender | |||
 Female/male | 5/3 | 2/7 | 0.234 |
Age, years | |||
 Median (range) | 63 (44–69) | 59 (23–78) | 0.797 |
Sunitinib Tx, cycles | |||
 Median (range) | 13.5 (6–23) | 2 (1–6) | 0.001 |
ORR | |||
 CR/PR | 7 | 2 | |
 SD | 1 | 2 | |
 PD | 0 | 5 | 0.012 |
50% PFS, months | Not reach(⩾14.9) | 2.3 | 0.004 |
Thyroid status at baseline | |||
 Hypothyroidism | 3 | 1 | |
 Euthyroid | 4 | 8 | |
 Unknown | 1 | 0 | 0.243 |
TSH at baseline, mIU l–1 | |||
 Median (range) | 3.62 (0.61–10.14) | 1.57 (0.52–8.65) | 0.314 |
Thyroid volume at baseline, ml | |||
 Median (range) | 13.0 (7.8–18.5) | 13.6 (5.8–21.0) | 0.797 |
Thyroid status during | |||
 Sunitinib-Tx | |||
Hypothyroidism | 8a | 1 | |
Euthyroid | 0 | 8 | 0.001 |
Maximum TSH during | |||
 Sunitinib-Tx, mIU l–1 | |||
Median (range) | 37.84 (4.69–230.89) | 3.51 (1.73–12.72) | 0.001 |
Supplement of L-T4 | |||
 During sunitinib-Tx | 7 | 1 | 0.008 |